system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Actins, Animals, Biocompatible Materials, Capillaries, Disease Models, Animal, Drug Carriers, Hindlimb, Humans, Ischemia, Lactic Acid, Laser-Doppler Flowmetry, Male, Mice, Mice, Inbred C57BL, Muscle, Skeletal, Neovascularization, Physiologic, Perfusion, Platelet Endothelial Cell Adhesion Molecule-1, Polyglycolic Acid, Polylactic Acid-Polyglycolic Acid Copolymer, Polymers, Vascular Endothelial Growth Factor A.
user
Does sustained vascular endothelial growth factor delivery enhance angiogenesis and perfusion in ischemic hind limb? Context: We hypothesized that sustained delivery of vascular endothelial growth factor (VEGF) using a polymer [85:15 poly(lactide-co-glycolide) (PLG)] would enhance angiogenesis and improve perfusion of ischemic tissue. C57BL/6J mice (n = 20/group) underwent unilateral hind limb ischemia surgery and were randomized to groups of no scaffold implantation (0-Implant), unloaded scaffold implantation (Empty-PLG), or implantation of scaffolds incorporating 3 microg of VEGF165 (PLG-VEGF). Endpoints included laser Doppler perfusion imaging (LDPI, ischemic/nonischemic limb, %), local vessel counts, immunohistochemistry for CD31, and alpha-smooth muscle actin. In vitro release kinetics of VEGF from PLG was also measured. PLG-VEGF resulted in improved lower extremity perfusion vs. controls as measured by LDPI% at 7, 14, 21, and 28 days (p < 0.05). PLG-VEGF was associated with significantly greater percentage of vessels staining for CD31 and alpha-smooth muscle actin compared to the Empty-PLG or 0-Implant (p < 0.05 for both).
assistant
The PLG-VEGF scaffolds resulted in sustained VEGF delivery, improved tissue perfusion, greater capillary density, and more mature vasculature compared to the controls. The sustained-release PLG polymer vehicle is a promising delivery system for therapeutic neovascularization applications. Final Decision: yes